Clinical trials have established a drug which 'reboots' a person's immune system as an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published in the journal iThe Lancet/i. The new studies, sponsored by Genzyme (a Sanofi company) ...Thursday, 1 November 2012
Clinical Trials Prove New Multiple Sclerosis Drug Effective Where First-line Therapy Failed
Clinical trials have established a drug which 'reboots' a person's immune system as an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published in the journal iThe Lancet/i. The new studies, sponsored by Genzyme (a Sanofi company) ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment